4th Quarter - Report

DIALYSIS PATIENT CITIZENS for DIALYSIS PATIENT CITIZENS

Firm
Client
Income
—
Expenses
$10,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Urge Congress to avoid sequestration and rebasing to ensure ESRD patient access and quality of care H.R. 6482 - to better reflect the impact of prevention in scoring potential legislation Address reimbursement cuts restricting access to intradialytic parenteral therapy (IDPN) & intraperitoneal parenteral nutrition (IPN)

LobbyistCovered position, as disclosed
HRANT JAMGOCHIAN —
CARRIE E LAMB —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); Internal Revenue Service (IRS); Health Resources & Services Administration (HRSA); White House Office; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Treasury, Dept of

Bills named: H.R. 6482 (112th)

Health Issues HCR

Coverage of End Stage Renal Disease (ESRD) in Essential Health Benefits Application of premium tax credits and cost-sharing subsidies for ESRD patients in health exchanges Ensuring adequacy of networks and consumer protections for ESRD patients in the exchanges S. 2163 / H.R. 6011 - To promote equitable access, prevention and research for kidney disease patients

LobbyistCovered position, as disclosed
HRANT JAMGOCHIAN —
CARRIE E LAMB —

Contacted: Treasury, Dept of; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; White House Office; Centers For Medicare and Medicaid Services (CMS); SENATE; Health Resources & Services Administration (HRSA); Internal Revenue Service (IRS)

Bills named: S. 2163 (112th), H.R. 6011 (112th)

Medical/Disease Research/Clinical Labs MED

Supporting innovative pilots to reduce and potentially prevent ESRD, as well as improve patient quality of life Importance of anemia management for ESRD patients Prioritizing role of patients in the Quality Incentive Program (QIP) Prioritize patient safety in developing procedure for approval of "generic" IV Iron

LobbyistCovered position, as disclosed
HRANT JAMGOCHIAN —

Contacted: Health & Human Services, Dept of (HHS); White House Office; Food & Drug Administration (FDA); Treasury, Dept of; SENATE; Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

S. 1454 / H.R. 2969 - Extend Medicare coverage of immunosuppressive medications for kidney transplant patients S. 3271 - Extend guaranteed issue of Medigap policies for kidney disease patients Potential incentives for innovation in ESRD bundled payment system Transition of oral-only medications into ESRD bundle

LobbyistCovered position, as disclosed
HRANT JAMGOCHIAN —
CARRIE E LAMB —

Contacted: Health & Human Services, Dept of (HHS); Treasury, Dept of; Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); White House Office; Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 2969 (112th), S. 1454 (112th), S. 3271 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.